Vinegar Co-ingestion in Type 2 Diabetes
The Effect of Vinegar Co-ingestion on Postprandial Glucose Control in Type 2 Diabetes Patients
1 other identifier
interventional
12
1 country
1
Brief Summary
The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable type-2-diabetes-mellitus
Started Sep 2010
Shorter than P25 for not_applicable type-2-diabetes-mellitus
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
January 17, 2011
CompletedFirst Posted
Study publicly available on registry
January 19, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedResults Posted
Study results publicly available
October 3, 2011
CompletedOctober 3, 2011
August 1, 2011
6 months
January 17, 2011
July 20, 2011
August 25, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
Postprandial Glycemic Incremental Area Under the Curve
area under the plasma glucose concentration curve, above the baseline plasma glucose, measured over 2 hr following ingestion of a the intervention beverages
2 hr
Study Arms (2)
vinegar co-ingestion
EXPERIMENTAL25 ml vinegar is added to glucose containing beverage
Placebo co-ingestion
PLACEBO COMPARATOR25 ml vinegar is substituted by 25 ml water
Interventions
25 ml water co-ingested with a glucose-containing beverage
25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
Eligibility Criteria
You may qualify if:
- male type 2 diabetes
- overweight or obese
- yrs
You may not qualify if:
- incident cardiovascular events during last year
- peptic ulcer, duodenal ulcer, oesophageal reflux
- antacids, H2 receptor blocker, proton pump inhibitors, NSAIDS, prokinetic agents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Maastricht University Medical Centre
Maastricht, Limburg, 6200 MD, Netherlands
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Drs. Jan-Willem van Dijk
- Organization
- Maastricht University Medical Centre
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2011
First Posted
January 19, 2011
Study Start
September 1, 2010
Primary Completion
March 1, 2011
Study Completion
March 1, 2011
Last Updated
October 3, 2011
Results First Posted
October 3, 2011
Record last verified: 2011-08